NEOS Investment Management LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

NEOS Investment Management LLC boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 29.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,891 shares of the medical equipment provider's stock after purchasing an additional 2,485 shares during the quarter. NEOS Investment Management LLC's holdings in Zimmer Biomet were worth $1,150,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. CKW Financial Group boosted its stake in Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock worth $101,000 after acquiring an additional 100 shares in the last quarter. Romano Brothers AND Company grew its stake in shares of Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after buying an additional 102 shares during the period. Dorsey & Whitney Trust CO LLC increased its position in Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares in the last quarter. M&T Bank Corp grew its stake in Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after acquiring an additional 108 shares during the period. Finally, Dakota Wealth Management increased its holdings in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock valued at $1,016,000 after acquiring an additional 122 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Truist Financial reiterated a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Stock Up 0.1 %

NYSE:ZBH traded up $0.11 during trading hours on Thursday, reaching $112.61. 537,649 shares of the company traded hands, compared to its average volume of 1,566,460. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $130.89. The stock has a market capitalization of $22.42 billion, a P/E ratio of 25.31, a P/E/G ratio of 1.95 and a beta of 1.04. The business's 50-day moving average price is $107.35 and its two-hundred day moving average price is $107.18. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company posted $2.20 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.